Long-Acting Injectable HIV Therapy Outcomes Among Persons With HIV Who Have Adherence Challenges to Oral Antiretroviral Therapy
Long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) may improve outcomes among persons with human immunodeficiency virus (PWH) with adherence difficulties to oral therapy. In this real-world observational study, over 85% of PWH remained on therapy and virally suppressed 48 weeks after initiating LAI-CAB/RPV. Providers should consider LAI therapy among PWH with adherence difficulties.
Authors
- Afsana Karim
- Thomas Martin (ORCID: https://orcid.org/0000-0002-5935-2348)
- Laura P Bamford (ORCID: https://orcid.org/0000-0001-5988-8372)
- Lucas Hill (ORCID: https://orcid.org/0000-0002-5689-5865)
- Elizabeth Hastie (ORCID: https://orcid.org/0000-0001-6587-6968)
Institutions
- University of California System (US)
- University of California San Diego (US)
- Department of Veterans Affairs (AU)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1093/cid/ciaf120
- Citations
- 9
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 12.57